Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
Key facts
- Who runs it
- Duke University
- Where
- Columbus, Gainesville, Hackensack, and San Francisco, United StatesSee the 4 sitesAlso in 3 other countries, 3 sites
- Trial code
- NCT06654882
- EU 2025-520923-25-00
- U1111-1322-4869
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 400 people, planned
- Started
- 9 Jan 2026
- Expected to end
- Nov 2029
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- TNFi (Tumor Necrosis Factor inhibitor) medication
- Abatacept
- Tocilizumab
- Tofacitinib
- Record updated
- 21 October 2026
Who can take part
- Age
- 2 years to 21 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Polyarticular course JIA
- Moderate or high-disease activity (cJADAS10 >5) despite treatment with an initial TNFi for ≥2 months
- Age ≥2 years and <21 years and weight ≥ 10kg
- No systemic glucocorticoids or systemic glucocorticoids at a stable dose of ≤0.2 mg/kg/day (maximum 10 mg/day) for ≥2 weeks prior to baseline visit
- Documented informed consent/assent obtained from the parent/caregiver/patient
Who cannot take part
- Active tuberculosis (TB) or a history of incompletely treated TB; Purified Protein derivative (PPD) or QuantiFERON-TB positive patients (without active TB) unless it is documented that the patient has been adequately treated for TB and can start treatment with a biologic agent, based on the medical judgment of the site investigator and/or an infectious disease specialist; suspected extrapulmonary TB infection; or at high risk of contracting TB, such as close contact with individual with active or latent TB
- Prior treatment with more than one TNFi molecule; exposure to more than one biosimilar of the same TNFi molecule is allowed
- Prior treatment with non-TNFi bDMARDs and/or any JAKi
- Any active acute, subacute, chronic, or recurrent bacterial, viral, or systemic fungal infection or any major episode of infection requiring hospitalization or treatment during screening or treatment with IV antibiotics completed within 4 weeks of the screening visit or oral antibiotics completed within 2 weeks of the screening visit
- Any live attenuated vaccine, such as varicella-zoster, oral polio, measles, mumps or rubella vaccines, within 4 weeks prior to the baseline visit
- Any medical history that may be considered a contraindication/safety concern with the use of adalimumab, etanercept, tofacitinib, ABA, or an IL-6 inhibitor or their biosimilars. In particular, subjects at known high risk for venous thromboembolism will be excluded, including recent heart failure or prior myocardial infarction, known inherited thrombotic risk factors, history of venous thromboembolism (deep venous thrombosis or pulmonary embolism, undergoing major surgery, or are chronically immobilized)
- History of or currently active inflammatory bowel disease
- History of or currently active psoriasis
- History of or currently active sacroiliitis
- History of or current malignancy
- History of hypersensitivity or allergic reaction to any study drug or any of its excipients (inactive ingredients)
- Aspartate aminotransferase (AST) or alanine transaminase (ALT) ≥3 × upper limit of normal (ULN) for age and sex
- Serum creatinine >1.5 × ULN for age and sex
- Platelet count <150 × 103/μL (<150,000/mm3)
- Hemoglobin <7.0 g/dL (<4.3 mmol/L)
- White blood cell (WBC) count <3,000/mm3 (<3.0 × 109/L)
- Neutrophil count <1,500/mm3 (<1.5 × 109/L)
- Systemic JIA
- Enthesitis-related arthritis/juvenile spondyloarthritis (2001 International League of Associations for Rheumatology [ILAR] criteria)30
- Active uveitis within 3 months of the baseline visit
- Pregnant or breastfeeding
- Sexually active females of childbearing potential who refuse to use at least one required contraception method (See Contraception paragraph 8.9 for definition of childbearing potential and details)
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 21 years old?
Where in United States
Also in 3 other countries, 3 sites
- Nationwide Children's HospitalColumbus, United StatesContact: Study CoordinatorTaking people
- University of FloridaGainesville, United StatesContact: Study CoordinatorTaking people
- Hackensack Meridian Health - Joseph M. Sanzari Children's HospitalHackensack, United StatesContact: Clinical Research CoordinatorTaking people
- University of California San Francisco Pediatric RheumatologySan Francisco, United StatesContact: Study CoordinatorTaking people
About the trial
What the trial wants to find out
This study is an open-label, randomized, multicenter trial that incorporates a multi-arm design comparing each of 3 non-TNFi (Tumor Necrosis Factor inhibitor) medications to a second TNFi (active control) within a sequential multiple assignment randomized trial design with 2 randomization stages corresponding with clinical decision points. The first randomization addresses whether each of the 3 non-TNFi medications is superior to treatment with a second TNFi. The second randomization allows identification of optimal sequential use of biologics (treatment strategies).
The 4 groups in the trial
- Second TNFi (Tumor Necrosis Factor inhibitor) medicationExisting treatment, for comparison
Adalimumab originator or biosimilar; etanercept originator or biosimilar depending on which TNFi the participant had failed.
Treatment: TNFi (Tumor Necrosis Factor inhibitor) medication
- AbataceptExisting treatment, for comparison
The 50 mg, 87.5 mg and 125 mg SQ doses will be available for weight-based dosing. All participants randomized to abatacept in the first or second stage randomization will receive abatacept SQ weekly at a dosage based on the participant's body weight
- Tocilizumab originator or biosimilarExisting treatment, for comparison
Tocilizumab will be provided in prefilled syringes (162 mg tocilizumab/0.9 mL solution). All participants randomized to tocilizumab in the first or second stage randomization will be receiving 1 prefilled syringe (162 mg) with a dosing interval based on the body weight criteria.
Treatment: Tocilizumab
- TofacitinibExisting treatment, for comparison
Tofacitinib will be provided as oral tablets (tofacitinib citrate 5 mg) and as an oral solution (1 mg/mL). All participants randomized to tofacitinib in the first or second stage randomization will receive tofacitinib oral tablets or oral solution twice daily, approximately 12 hours apart, in the morning and evening, at a dosage based on the participant's body weight .
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Criteria questions
- Built from NCT06654882, who can take part
- Record updated
- 21 October 2026